Investor Presentation May 2025 .头. Astrana Health Forward Looking Statements This presentation contains for ward-lookingstatements within the meacing of the Pivate Securities Lifyation Reform Att of 1985Section 274 of the Securities Aut and Section looding statements in blude any vatatements about the Company is business, financial conditibin, operating results, plans, odpectives, expectations and intentions, expansi market, our ability to successful Jr corrupted and realize the benefits of anticipated a ap ...

China Healthcare | Asia Pacific 11th Round of National Drug VBP Around the Corner Key Takeaways Drug selection criteria aims to balance pricing against clinical practice considerations: Among the 75 drugs proposed, 14 drugs will be further evaluated ( Exhibit 1 ), including: 1) five whose generic products have narrower indications approved than the originators' drugs. The reported volume for these drugs may be limited to the scope of commonly-approved indications; 2) nine generics are considered to have rel ...

Virginia-based pediatric care network gains more complete picture of a child's health history, supports early interventions, and enhances patient engagement Solution helps network achieve value-based care objectives Fortify Children's Health plans to add more capabilities from the Oracle Health Data Intelligence suite to help them gain insights into the social determinants of health among pediatric patients—the conditions in which children live, learn, play, and grow that affect their health and wellbeing— ...

AST SpaceMobile TodayASTSAST SpaceMobile$53.22 +3.02 (+6.02%) 52-Week Range$9.32▼$54.05Price Target$43.73Add to WatchlistShares of AST SpaceMobile NASDAQ: ASTS have delivered a powerful performance recently, posting triple-digit percentage gains that have captured the market's attention. This rally is being supported by a surge in trading volume and intense options activity, creating a dynamic where bullish conviction is meeting investor skepticism head-on. AST’s recent market movements seem to be more tha ...

Global Leader in Advanced Security and Surveillance Technology & Industrial Services NASDAQ Listed | CETX Investor Presentation January 2025 | Share Price1 | $2.84 | | --- | --- | | Market Cap1 | $4.9M | | FY 2024 Revenue2 | $66.9M | | Cash & Cash Equivalents2 | $3.9M | | Shares Outstanding3 | 1.7M | | Float3 | 1.7M | | Headquarters | Hauppauge, NY | | Employees | 281 | Safe Harbor Statement This presentation may contain forward looking statements that involve numerous risks and uncertainties. Actual result ...

Core Insights - Spirit Blockchain Capital Inc. has appointed Don Stewart, CFA, as an Independent Board Member, enhancing its governance and strategic execution [1][2] - Mr. Stewart's extensive experience in capital markets, regulatory compliance, and financial innovation is expected to bolster investor trust and transparency within the company [2][3] - The appointment aligns with Spirit's long-term vision of establishing a compliant, investor-focused digital asset institution [6] Company Overview - Spirit Blockchain Capital Inc. is a publicly listed company focused on bridging traditional finance and digital assets through tokenization and regulated investment strategies [7] - The company operates under a multi-jurisdictional structure, emphasizing regulatory alignment in Switzerland, Canada, and globally [7] - Spirit provides capital markets access, token structuring, and digital asset management solutions to institutional and accredited investors [7] Leadership and Governance - Don Stewart's background includes serving as a Member of Parliament and leading the Market Surveillance team at the Canadian Investment Regulatory Organization [3][4] - His role on the Board's Compensation Committee and Business Development Committee will directly influence Spirit's shareholder alignment and capital strategy [5] - The CEO of Spirit Blockchain, Lewis Bateman, highlighted Stewart's appointment as a significant advancement for the Board and shareholders [4]

Key Takeaways Energy Transfer earns nearly 90% of its income from fee-based contracts, ensuring stable cash flows. ET's infrastructure in key basins secures long-term deals, aiding visibility into future earnings. ET's units trade at 10.17X EV/EBITDA TTM, a discount to the industry average of 11.39X.Energy Transfer LP (ET) , a U.S. midstream operator, benefits significantly from its reliance on fee-based contracts across the diversified asset portfolio. These contracts, which form the backbone of its reve ...

[Music] The first bird I ever had a conversation with was a western metallark when I was 8 years old. I remember that moment so vividly. It was in the short grass prairie behind my house where I spent most of my childhood surrounded by nature.I was out there for hours listening and trying to imitate every bird around me. And without even realizing it, I was learning a new language, one bird sound at a time. [Music] The following year at summer camp, a boy there taught me how to do the water drop noise.And o ...

Key Takeaways Cleveland-Cliffs commissions a $150M Vertical Stainless Bright Anneal Line at Coshocton Works. The new line uses a 100% hydrogen atmosphere and hydrogen recovery to enhance steel processing. This investment targets premium stainless steel for automotive and critical appliance applications.Cleveland-Cliffs Inc. (CLF) has commissioned its new cutting-edge Vertical Stainless Bright Anneal Line at its Coshocton Works facility in Coshocton, OH. This $150 million capital investment has been comple ...

Pipeline Programs and Milestones - Nuvalent is advancing parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development, with potential for first FDA approval in 2026[4] - The company plans to report pivotal data for TKI pre-treated ROS1+ NSCLC from the ARROS-1 trial in 1H 2025 and complete rolling NDA submission in Q3 2025[14] - Topline pivotal data for TKI pre-treated ALK+ NSCLC from the ALKOVE-1 trial is anticipated by year-end 2025, with ALKAZAR Phase 3 trial for TKI-naïve ALK+ NSCLC planned to initiate in early 2H 2025[14, 205] - NVL-330 for HER2-altered NSCLC is in Phase 1a/1b investigation, with additional discovery research programs ongoing[12, 205] Zidesamtinib (NVL-520) for ROS1+ NSCLC - In TKI pre-treated ROS1+ NSCLC patients, the ORR was 44% (51/117), with 78% (95% CI: 62, 88) DOR ≥ 12 months and 62% (95% CI: 28, 84) DOR ≥ 18 months[73] - In patients with prior crizotinib or entrectinib only ± chemotherapy, the ORR was 51% (28/55), with 93% (95% CI: 74, 98) DOR ≥ 12 months and 93% (95% CI: 74, 98) DOR ≥ 18 months[80] - Zidesamtinib demonstrated CNS activity, with an IC-ORR of 48% (27/56) in any prior ROS1 TKI ± chemotherapy and 85% (11/13) in prior crizotinib only ± chemotherapy[90] - The safety profile of zidesamtinib was generally well-tolerated, with peripheral edema reported in 36% of patients, constipation in 17%, blood CPK increased in 16%, fatigue in 16%, and dyspnea in 15%[96] - In TKI-naïve patients with ROS1+ NSCLC, the ORR was 89% (31/35), with 96% (95% CI: 76, 99) DOR ≥ 6 months and 96% (95% CI: 76, 99) DOR ≥ 12 months[103] Neladalkib (NVL-655) for ALK+ NSCLC - In a heavily pre-treated ALK+ solid tumor population, 51% had any secondary ALK mutation, 26% had a compound ALK mutation, and 56% had a history of CNS metastasis[140, 141] - In all NSCLC response evaluable patients, across all doses, the ORR was 38% (39/103), with a mDOR of 144 months and 78% DOR > 6 months[149] - In patients with any ALK resistance mutation at RP2D, the ORR was 55% (12/22), with a mDOR not reached and 100% DOR > 6 months[158] - The preliminary safety profile of neladalkib was consistent with its ALK-selective design, with ALT increased in 34% of patients, AST increased in 30%, constipation in 16%, dysgeusia in 13%, and nausea in 12%[166] Market Overview - The combined worldwide sales for ALK and ROS1 TKIs in 2024 were approximately $31 billion[27]